GCG and Alzheimer disease: The knowledge gained could guide the design of trials aimed at demonstrating GLP-1 RA efficacy, particularly where a specific subgroup (eg, individuals with high cardiovascular risk or high levels of systemic inflammation or genetic risk for AD) is shown to be most likely to benefit from them.